Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is in a strong position for long-term success due to the company's strong financial performance, focused strategy, and promising technology platform. The company's profitability targets for 2026 showcase its ability to successfully manage the expected cost trends for Medicare Advantage members, driven by the utilization of its proprietary software platform, Clover Assistant. With a majority of its members utilizing Clover Assistant-enabled physicians and strong retention rates, Clover is well-positioned to continue its growth and profitability in the coming years. While there are potential headwinds for 2027, including being paid as a 3.5-star plan and possible regulatory changes, management remains confident in the company's ability to effectively manage these challenges and maintain its profitability. With a strong base of returning members and a growing cohort, Clover shows potential for sustained profitability in the future.

Bears say

Clover Health Investments is facing several challenges that can negatively affect its financial performance and market position. The company's profitability is under pressure due to higher medical costs caused by increased utilization. Regulatory changes to the Medicare Advantage program could also impact the company's financial performance. Furthermore, the company has an unproven track record of sustained profitability in a highly competitive market. As a result, the stock may not be a profitable investment option in the long term.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.